For research use only. Not for therapeutic Use.
Primaquine Diphosphate（Cat No.:I004391）is an antimalarial agent effective against the liver stages of Plasmodium species, including P. vivax and P. ovale. It works by generating reactive oxygen species and disrupting mitochondrial function, targeting dormant hypnozoites to prevent relapses of malaria. Primaquine Diphosphate is also used for the gametocidal stages of P. falciparum, helping to reduce malaria transmission. Administered orally, it is typically part of radical cure regimens. Its efficacy, combined with careful monitoring to avoid hemolysis in G6PD-deficient individuals, makes it a critical tool in malaria eradication efforts.
| Catalog Number | I004391 |
| CAS Number | 63-45-6 |
| Synonyms | 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid |
| Molecular Formula | C15H21N3O • 2H3PO4 |
| Purity | ≥95% |
| Target | Parasite |
| Solubility | H2O: ≥ 35 mg/mL |
| Storage | 2-8°C |
| IUPAC Name | 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid |
| InChI | InChI=1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4) |
| InChIKey | GJOHLWZHWQUKAU-UHFFFAOYSA-N |
| SMILES | CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2.OP(=O)(O)O.OP(=O)(O)O |
| Reference | </br>1:Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design. Duque MD, Kreidel RN, Taqueda ME, Baby AR, Kaneko TM, Velasco MV, Consiglieri VO.Pharm Dev Technol. 2013 Sep-Oct;18(5):1247-54. doi: 10.3109/10837450.2012.693508. Epub 2012 Jun 7. PMID: 22670808 </br>2:Analysis of quinocide in unprocessed primaquine diphosphate and primaquine diphosphate tablets using gas chromatography-mass spectrometry with supersonic molecular beams. Brondz I, Fialkov AB, Amirav A.J Chromatogr A. 2009 Jan 30;1216(5):824-9. doi: 10.1016/j.chroma.2008.11.043. Epub 2008 Nov 21. Erratum in: J Chromatogr A. 2009 Mar 20;1216(12):2609-10. PMID: 19108846 </br>3:Nature of the main contaminant in the drug primaquine diphosphate: SFC and SFC-MS methods of analysis. Brondz I, Ekeberg D, Bell DS, Annino AR, Hustad JA, Svendsen R, Vlachos V, Oakley P, Langley GJ, Mohini T, Amaury CG, Mikhalitsyn F.J Pharm Biomed Anal. 2007 Feb 19;43(3):937-44. Epub 2006 Oct 31. PMID: 17079107 </br>4:Primaquine diphosphate: comprehensive profile. Al-Badr AA.Profiles Drug Subst Excip Relat Methodol. 2005;32:153-208. doi: 10.1016/S0099-5428(05)32007-7. Epub 2006 Jan 17. No abstract available. PMID: 22469087 </br>5:In vitro and in vivo evaluation of albumin-encapsulated primaquine diphosphate prepared by nebulization into heated oil. Green MD, D/’Souza MJ, Holbrook JM, Wirtz RA.J Microencapsul. 2004 Jun;21(4):433-44. PMID: 15513749 </br>6:Nature of the main contaminant in the anti malaria drug primaquine diphosphate: a qualitative isomer analysis. Brondz I, Mantzilas D, Klein U, Ekeberg D, Hvattum E, Lebedeva MN, Mikhailitsyn FS, Souleimanov GD, Røe J.J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Feb 5;800(1-2):211-23. PMID: 14698257 </br>7:Dissociation and electrooxidation of primaquine diphosphate as an approach to the study of anti-chagas prodrugs mechanism of action. La-Scalea MA, Chin CM, Cruz ML, Serrano SH, Ferreira EI.Bioelectrochemistry. 2001 Jan;53(1):55-9. PMID: 11206925 </br>8:Characterization, in vitro and in vivo studies on primaquine diphosphate liposomes. Arica B, Ozer AY, Ercan MT, Hincal AA.J Microencapsul. 1995 Sep-Oct;12(5):469-85. PMID: 8544091 </br>9:Structure of the anti-malarial drug primaquine diphosphate. Rubin JR, Swaminathan P, Sundaralingam M.Acta Crystallogr C. 1992 Feb 15;48 ( Pt 2):379-82. PMID: 1627276 </br>10:Primaquine diphosphate: inhibition of Newcastle disease virus replication. Burdick JR, Durand DP.Antimicrob Agents Chemother. 1974 Oct;6(4):460-4. PMID: 4157345 Free PMC Article |
